Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.
-
Bennett CL, Schoen MW, Hoque S, Witherspoon BJ, Aboulafia DM, Hwang CS, Ray P, Yarnold PR, Chen BK, Schooley B, Taylor MA, Wyatt MD, Hrushesky WJ, Yang YT. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
-
Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
-
Qureshi ZP, Nagai S, Bennett CL. Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done? JAMA Oncol. 2019 03 01; 5(3):297-298.
-
Chen BK, Yang YT, Bennett CL. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition. Drugs. 2018 Nov; 78(17):1777-1781.
-
Chen B, Yang YT, Bennett C. Friction in the Path to Use of Biosimilar Drugs. N Engl J Med. 2018 05 31; 378(22):2148.
-
Gani L, Lau E, Luk A, Sobrepena L, Tran QK, Kesavadev J, Jia W, Yu W, Tsang CC, Mukhopadhyay M, Jha S, Sheu W, Ho YK, Nguyen TK, Ozaki R, So WY, Kwan C, Fu AWC, Mirasol R, Phatak SR, Kumar KMP, Aravind S, Janakiraman H, Chan JCN. Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program. J Diabetes Investig. 2018 Nov; 9(6):1312-1322.
-
Yang YT, Chen B, Bennett CL. Biosimilars-Curb Your Enthusiasm. JAMA Oncol. 2017 11 01; 3(11):1467-1468.
-
Chen B, Yang YT, Bennett CL. Challenges to Biosimilar Substitution. JAMA. 2017 09 26; 318(12):1186.
-
Bennett CL, Sartor OA, Armitage JO, Kantarjian H. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA. Lancet Oncol. 2017 01; 18(1):22-23.
-
Bennett CL, Chen B, Hermanson T, Georgantopoulos P, Sartor OA. Japanese regulatory authority's perspective on biosimilars - authors' reply. Lancet Oncol. 2015 Mar; 16(3):e102.